Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20016164 | 0.79 | KDM1A (0.44) | KDM1AKDM1BRIPK1NTRK1JAK2 | |
| SCHEMBL4294177 | 0.79 | KDM1A (0.44) | KDM1AKDM1BRIPK1NTRK1JAK2 | |
| SCHEMBL17772161 | 0.76 | KDM1A (0.42) | KDM1AKDM1BRIPK1NTRK1JAK2 | |
| SCHEMBL4104823 | 0.75 | KDM1A (0.41) | KDM1AKDM1BRIPK1NTRK1JAK2 | |
| SCHEMBL17359922 | 0.72 | NTRK1 (0.44) | KDM1AKDM1BNTRK1JAK2OPRM1 | |
| SCHEMBL16310668 | 0.72 | NTRK1 (0.44) | KDM1AKDM1BNTRK1JAK2OPRM1 | |
| SCHEMBL21400027 | 0.72 | CHRNB2 (0.46) | NTRK1JAK2NTRK3 | |
| SCHEMBL21400030 | 0.72 | CHRNB2 (0.46) | NTRK1JAK2NTRK3 | |
| SCHEMBL4291250 | 0.72 | CHRNB2 (0.46) | NTRK1JAK2NTRK3 | |
| SCHEMBL28174506 | 0.71 | OPRM1 (0.49) | KDM1AKDM1BNTRK1JAK2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796724-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114069-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | KDM1A 2479/4885KDM1B 3219/4885RIPK1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.